Ferrara, Felicetto <br/><br/>
Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?  [electronic resource] 

 -  Hematological oncology  Mar 2014 
 - 1-9 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Review 
<br/><br/><label>ISSN: </label>1099-1069 
<br/><br/><label>Standard No.: </label>10.1002/hon.2046  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Age Factors<br/>Aged<br/>Antimetabolites, Antineoplastic--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Azacitidine--administration & dosage<br/>Combined Modality Therapy<br/>Comorbidity<br/>Consolidation Chemotherapy<br/>DNA Methylation--drug effects<br/>DNA, Neoplasm--metabolism<br/>DNA-Cytosine Methylases--antagonists & inhibitors<br/>Decitabine<br/>Enzyme Inhibitors--administration & dosage<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Middle Aged<br/>Molecular Targeted Therapy<br/>Multicenter Studies as Topic<br/>Neoplasm Proteins--antagonists & inhibitors<br/>Prognosis<br/>Randomized Controlled Trials as Topic<br/>Remission Induction<br/>Survival Rate<br/>Treatment Outcome